Clinical trials: Pregnancy Anemia
Intermittent Fasting, Dyslipidemias
Intermittent Fasting in Dyslipidemia
World Health Organization report notifies of the escalating global burden of cardiovascular diseases (CVD), projecting that it will become the major worldwide cause of death and disability by 2020.
- Conditions
- Intermittent Fasting, Dyslipidemias, HDL Cholesterol, Low Serum, Hepatic Enzymes and Function Abnormalities
- Trial name
- NCT03805776
- Testing
- Fasting (diet restruction for specific period)
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Aga Khan University
Anaemia
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent
GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease.
- Trial name
- NCT02689206
- Testing
- GSK1278863
- Where
- 38 sites in United States, Canada and 3 more
- Volunteers
- 103 people
- Sponsor
- GlaxoSmithKline
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
Sickle Cell Disease
Crizanlizumab Pregnancy Outcomes Intensive Monitoring
This was a non-interventional study to evaluate pre-specified pregnancy and infant outcomes in women treated with crizanlizumab during pregnancy or within 105 days before the last menstrual period (LMP).
- Trial name
- PRIM (NCT07554547)
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications
The primary objective of this study will be to evaluate the drug-drug interaction potential of CCX168 with concomitant medications, as either a perpetrator or a victim, following oral administration of CCX168 to healthy…
- Trial name
- NCT06004947
- Testing
- CCX168, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Malaria in Pregnancy, HIV Infections
Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda
There is conflicting evidence regarding the influence of HIV infection on the success of malaria prevention in pregnancy and effect on pregnancy outcome.
- Trial name
- NCT00132535
- Testing
- sulfadoxine-pyrimethamine intermittent preventive treatment, chloroquine
- Where
- Uganda
- Volunteers
- 2,548 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Anemia, Iron Deficiency Anaemia in Childbirth
Impact of Iron Supplementation During Pregnancy
During pregnancy, iron deficiency is the most common cause of anemia. Anemia is very common during pregnancy and after childbirth.
- Conditions
- Anemia, Iron Deficiency Anaemia in Childbirth, Pregnancy
- Trial name
- NCT07814378
- Testing
- Iron
- Where
- 2 sites in Germany
- Volunteers
- 800 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Premature, Placental Transfusion
Evaluation of Placental Transfusion Techniques in Prevention of Prematurity Related Complications and Effect on Their Hematological Profile
The objective of this study is to evaluate the general course and prognosis associated with different methods of placental transfusion (Intact umbilical cord milking, cut- umbilical cord milking and delayed cord clamping) in…
- Trial name
- NCT06812507
- Testing
- intact umbilical milking, cut umbilical milking, Delayed cord clamping
- Where
- Egypt
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Alexandria University
Iron Deficiency Anemia of Pregnancy, Iron Storage Disease
Analysis of the Effect of Iron Supplements on Iron Deficiency Anemia in Pregnancy
Subjects were tested for hemoglobin, ferritin, serum iron, transferrin saturation and reticulocyte count during routine prenatal examination at 24-26 weeks of gestation, and blood samples were taken for serum hepcidin detection…
- Trial name
- NCT05804071
- Testing
- Niferex
- Where
- China
- Volunteers
- 452 people, healthy volunteers welcome
- Sponsor
- Qianfoshan Hospital
Anemia
Treatment of Anemia in Diabetic Subjects With CKD
The purpose of this study is to compare the proportion of subjects receiving either Epoetin alfa (PROCRIT®) or placebo who are able to achieve a hemoglobin response, defined by at least a 1 gram/deciliter increase from baseline…
- Trial name
- NCT00240734
- Testing
- Epoetin alfa
- Volunteers
- 11 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Anemia, Anemia, Iron Deficiency
Iron Deficiency Anemia and Non-iron Deficiency Anemia in Pregnancy in India
This is a sub-study nested into the existing NICHD Global Network for Women's \& Children's Health Research Maternal Newborn Health (MNH) registry that is a prospective, observational population-based registry in Eastern…
- Conditions
- Anemia, Anemia, Iron Deficiency, Anemia of Pregnancy
- Trial name
- IDA & NIDA (NCT04708665)
- Where
- India
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Boston University Charles River Campus
Twin Monochorionic Diamniotic Placenta
Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation
The purpose of this study is to evaluate the safety and efficacy of the investigational fetoscopes used in patients undergoing fetoscopic selective laser photocoagulation for complicated monochorionic-diamniotic pregnancies.
- Trial name
- NCT06022510
- Testing
- Fetoscopy Sets for Anterior and Posterior Placentas
- Where
- United States
- Sponsor
- Michael A Belfort
Anemia, Chronic Kidney Disease
A Study of Luspatercept in People With Anemia
The researchers are doing this study to test whether luspatercept works to improve hemoglobin levels in people with anemia caused by chronic kidney disease (CKD).
- Trial name
- NCT07725497
- Testing
- Luspatercept
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Anemia, Renal Insufficiency, Chronic
Maintenance Treatment of Renal Anemia in Dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in comparison to darbepoetin alfa in dialysis subjects with renal anemia who are treated with Erythropoiesis-Stimulating Agents (ESAs).
- Trial name
- MIYABI HD-M (NCT03543657)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 53 sites in Japan
- Volunteers
- 229 people
- Sponsor
- Bayer
Iron Deficiency Anemia of Pregnancy
Lactoferrin Versus Ferrous Fumarate for Treatment of Mild to Moderate Iron Deficiency Anemia During Pregnancy
This study will conducted to evaluate and comparison between the effectiveness, safety and acceptability of lactoferrin alone, ferrous fumarate alone and combination of both for the treatment of mild to moderate IDA during…
- Trial name
- NCT03484845
- Testing
- Lactoferrin and ferrous fumarate
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Assiut University
Anemia of Chronic Kidney Disease
Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease
Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate efficacy and safety of Hemax PFS® (PFS: prefilled…
- Trial name
- NCT04036253
- Testing
- Erythropoietin alfa
- Where
- 11 sites in Argentina, Paraguay
- Volunteers
- 43 people
- Sponsor
- Bio Sidus SA
Atypical Hemolytic Uremic Syndrome (aHUS)
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
The purpose of the study is to assess the safety and efficacy of ravulizumab to control disease activity in adolescent and adult participants with aHUS who had not previously used a complement inhibitor.
- Trial name
- NCT02949128
- Testing
- Ravulizumab
- Where
- 37 sites in United States, Australia and 12 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical
Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions.
- Conditions
- Thrombotic Microangiopathies, Hemolytic Uremic Syndrome, Atypical, Hemolytic-Uremic Syndrome
- Trial name
- COMPETE (NCT04745195)
- Where
- Netherlands
- Volunteers
- 42 people
- Sponsor
- Maastricht University Medical Center
Anemia, Chronic Renal Failure
Safety & Efficacy of Peginesatide for Treatment of Anemia in Participants on Dialysis Not Receiving an ESA
The purpose of this study is to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease who are on dialysis and are not taking any treatment to increase their red…
- Conditions
- Anemia, Chronic Renal Failure, Chronic Kidney Disease
- Trial name
- NCT00680043
- Testing
- peginesatide, Epoetin Alfa
- Where
- 11 sites in Russia
- Volunteers
- 114 people
- Sponsor
- Affymax
Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome
Rituximab in Patients With Relapsed or Refractory TTP-HUS
The general objective of this study is to assess the efficacy and safety of Rituximab in the management of patients with refractory or relapsed thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS).
- Trial name
- NCT00531089
- Testing
- Rituximab
- Where
- 11 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Hamilton Health Sciences Corporation